These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1347330)

  • 21. [Effect of a proton pump inhibitor AG-1749 (lansoprazole) on intragastric pH: 24-hour intragastric pH monitoring].
    Kihira K; Yoshida Y; Kasano T; Taniguchi Y; Sato K; Kimura K; Hirose M; Koyama H
    Nihon Shokakibyo Gakkai Zasshi; 1991 Mar; 88(3):672-80. PubMed ID: 1646341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proton pump inhibitors: new drugs and indications.
    Mears JM; Kaplan B
    Am Fam Physician; 1996 Jan; 53(1):285-92. PubMed ID: 8546054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C
    Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastric acid secretion: activation and inhibition.
    Sachs G; Prinz C; Loo D; Bamberg K; Besancon M; Shin JM
    Yale J Biol Med; 1994; 67(3-4):81-95. PubMed ID: 7502535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of Acid Secretion by Lansoprazole and its Effects on Helicobacter pylori. II. Poster presentations from the 2nd International Colloquium on Proton Pump Inhibitors. Houston, Texas, September 29, 1994.
    J Clin Gastroenterol; 1995; 20 Suppl 2():S1-135. PubMed ID: 7594319
    [No Abstract]   [Full Text] [Related]  

  • 26. A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions.
    Yoshida N; Yoshikawa T; Tanaka Y; Fujita N; Kassai K; Naito Y; Kondo M
    Aliment Pharmacol Ther; 2000 Apr; 14 Suppl 1():74-81. PubMed ID: 10807407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the enantiomers of lansoprazole (AG-1749) on (H+ + K+)-ATPase activity in canine gastric microsomes and acid formation in isolated canine parietal cells.
    Nagaya H; Inatomi N; Nohara A; Satoh H
    Biochem Pharmacol; 1991 Oct; 42(10):1875-8. PubMed ID: 1660270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Relapse of peptic ulcer after quick healing induced by proton pump inhibitors].
    Tsukamoto Y; Niwa Y; Arisawa T
    Nihon Rinsho; 1992 Jan; 50(1):174-80. PubMed ID: 1371814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Studies on the intracellular pharmacodynamic properties of proton pump inhibitors and the inhibitory mechanism of acid secretion].
    Saito E; Matsuo Y
    Nihon Rinsho; 1992 Jan; 50(1):18-25. PubMed ID: 1311783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppressive effect of antiulcer agents on granulocytes--a role for granulocytes in gastric ulcer formation.
    Kawamura T; Miyaji C; Toyabe S; Fukuda M; Watanabe H; Abo T
    Dig Dis Sci; 2000 Sep; 45(9):1786-91. PubMed ID: 11052321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-vitro activity of lansoprazole against Helicobacter pylori.
    Figura N; Crabtree JE; Dattilo M
    J Antimicrob Chemother; 1997 May; 39(5):585-90. PubMed ID: 9184356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Submicroscopic aspects of the mechanism of inhibitors of H+/K+-ATPase in gastric parietal cells].
    Morozov IA
    Eksp Klin Gastroenterol; 2002; (3):94-100, 122. PubMed ID: 12353402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Investigation of the therapeutic use of proton pump inhibitor (PPI) by measurement of 24 hour the intra-gastric pH].
    Yamagata S
    Nihon Rinsho; 1992 Jan; 50(1):160-6. PubMed ID: 1347328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview.
    Dobrilla G; Di Fede F
    Clin Ther; 1993; 15 Suppl B():2-13. PubMed ID: 7911400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bactericidal activity of lansoprazole and omeprazole against Helicobacter pylori in vitro.
    Vogt K; Hahn H
    Arzneimittelforschung; 1998 Jun; 48(6):694-7. PubMed ID: 9689430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinico-pharmacological evaluation of omeprazole, as a proton pump inhibitor, compared with H2-blockers].
    Nakashima M; Kanamaru M
    Nihon Rinsho; 1992 Jan; 50(1):60-7. PubMed ID: 1347331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lansoprazole: a proton pump inhibitor.
    Garnett WR
    Ann Pharmacother; 1996 Dec; 30(12):1425-36. PubMed ID: 8968456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently.
    Tomiyama Y; Morii M; Takeguchi N
    Biochem Pharmacol; 1994 Nov; 48(11):2049-55. PubMed ID: 7802694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Proton pump inhibitor for maintenance therapy of peptic ulcer].
    Yanai H; Tada M; Okita K
    Nihon Rinsho; 1992 Jan; 50(1):167-73. PubMed ID: 1311782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.